Abstract
In late June 2024, the European Medicines Agency (EMA) recommended market authorization for a monovalent COVID-19 mRNA-vaccine based on JN.1 spike. We assessed immune responses in n=42 health-care workers (median age 47 years, interquartile range, IQR 19·5 years, 48% male), who in August 2024 were vaccinated with 30 μg of the updated mRNA omicron JN.1 vaccine (bretovameran, BioNTech/Pfizer, Mainz, Germany). Humoral immune responses were analyzed directly prior to and 13 days after vaccination.
The omicron JN.1 vaccination resulted in a significant 1·2-fold increase of anti-S IgG and 1·2-fold increase of omicron anti-S IgG (p<0·0001). To assess plasma neutralisation capacity, we employed a pseudovirus particle (pp) neutralisation assay including S proteins of seven SARS-CoV-2 lineages. Baseline response rates were 100% for XBB.1.5pp, 90% for JN.1pp and KP.2pp, 82% for KP.2.3pp, 92% for KP.3pp, and 72% for LB.1pp. Before JN.1 vaccination, particles bearing KP sublineage S proteins were slightly less efficiently neutralised compared with JN.1pp (median change, 1·2-fold to 2·6-fold), while LB.1pp neutralisation was 3-fold reduced, indicating antibody evasion. After vaccination, the response rates increased significantly for all pseudoviruses except XBB.1.5pp and KP.3pp. Thus, we observed a significant increase in neutralisation of JN.1pp, KP.2pp, KP.2.3pp, and LB.1pp, showing a median change of 2.2-fold, 3.8-fold, 3.3-fold, and 4.9-fold, respectively.
In summary, bretovameran increased anti-S IgG and strengthened neutralising responses against circulating SARS-CoV-2-variants, except for KP.3. We wish to point out that our study population exhibited high pre-vaccination omicron-related hybrid immunity and may not be representative of other populations. Our data supports the notion that the new mRNA vaccine against omicron JN.1 most likely increases protection against hospitalization and post-COVID sequelae caused by most current variants.
Competing Interest Statement
M.H., A.K., and S.P. conducted contract research (testing of vaccinee sera for neutralizing activity against SARS-CoV-2) for Valneva unrelated to this work. G.M.N.B. served as advisor for Moderna, S.P. served as advisor for BioNTech, unrelated to this work, A.D-J served as an advisor for Pfizer unrelated to this work. T.W. served as an advisor for Pfizer and received honoraria for seminars from Pfizer, both activities are unrelated to this work. The other authors declare no competing interests.
Clinical Trial
German Clinical Trial Register DRKS00021152
Funding Statement
G.M.N.B. and A.D.-J. acknowledge funding (Niedersaechsisches Ministerium fuer Wissenschaft und Kultur; 14-76103-184, COFONI Network, project 4LZF23), G.M.N.B. acknowledge funding by the European Regional Development Fund ZW7-85151373, and A.D.-J. acknowledge funding by European Social Fund (ZAM5-87006761). T.W. acknowledges funded by the DFG under Germany's Excellence Strategy EXC 2155 RESIST (Project 390874280). S.P. acknowledges funding by the EU project UNDINE (grant agreement number 101057100), the COVID-19-Research Network Lower Saxony (COFONI) through funding from the Ministry of Science and Culture of Lower Saxony in Germany (14-76103-184, projects 7FF22, 6FF22, 10FF22) and the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; PO 716/11-1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The CoCo Study and the analysis conducted for this article were approved by the Internal Review Board of Hannover Medical School (institutional review board no. 8973_BO-K_2020, last amendment Aug 2024)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All requests for raw and analysed data that underly the results reported in this article will be reviewed within four weeks by the CoCo Study Team, Hannover Medical School (cocostudie@mh-hannover.de) to determine whether the request is subject to confidentiality and data protection obligations. Data that can be shared will be released via a material transfer agreement.